Abstract:Abstract Background: Recently, more and more treatment strategies for Hepatocellular carcinoma (HCC) have emerged, but the therapeutic effect is still not satisfactory. This study is aimed to explore the mechanism of Interleukin 35 (IL-35) in promoting the progression of liver cancer and to explore the application value of IL-35 in the treatment of HCC.Methods: We used clinical tissue microarray (TMA) immunohistochemistry (IHC) to explore the prognostic value of IL-35 expression in patients with HCC. The effect of IL-35 on the function of HCC was explored by functional experiments including wound-healing assay, transwell, cell counting kit-8, cell adhesion assay and endothelial tube formation assay in vitro and mouse xenografts in vivo. And flow cytometry was used to study the effect of IL-35 on infiltrating immune cells in tumor. The molecular mechanism of the function of IL-35 on the progression of HCC was explored by sequencing, ELISA, WB, PCR and other technical means. Finally, through in vivo tumor animal experiments to explore the value of anti-IL-35 antibody and combined with anti-PD-1 antibody in the treatment of liver cancer.Results: High expression of IL-35 in patients with HCC were identified to be associated with poor prognosis. And we have found that IL-35 facilitated tumor progression by affecting neutrophil infiltration, angiogenesis, and CD8+ T-cell infiltration in a mouse model. Additionally, on the one hand C-C motif chemokine ligand 3 (CCL3) has been found to be a key factor mediating the recruitment of neutrophils by IL-35, on the other hand fibroblast growth factor 2 (FGF2) secreting by neutrophil when stimulated by IL-35 was also found to be the core cytokine to promote intratumoral angiogenesis. And IL-35 was also discovered to facilitated the adhesion of tumor to endothelial cells, with neutrophils further enhancing this effect in vitro and vivo. More important, anti-IL-35 antibody was found to be a valid treatment for HCC in xenograft tumor model, and it could give full play to the curative effect of 1:1＞2 when combination therapy with PD-1 antibody.Conclusion: Our data show that the expression of IL-35 in patients with HCC is an important tumor promoting factor. The application of anti-IL-35 antibody and treatment combined anti-IL-35 antibody with anti-PD-1 antibody have potential therapeutic value in the treatment of liver cancer.

APOBEC3B and IL-6 Form a Positive Feedback Loop in Hepatocellular Carcinoma Cells

Zinc Finger Protein 296 Promotes Hepatocellular Carcinoma Progression Via Intervening Interaction Between Macrophages and B Cells.

APOBEC3B Interaction with PRC2 Modulates Microenvironment to Promote HCC Progression.

Interleukin-6 Induced by YAP in Hepatocellular Carcinoma Cells Recruits Tumor-Associated Macrophages

Apobec3g Expression is Correlated with Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis

Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations

Correlation of APOBEC3 in Tumor Tissues with Clinico-Pathological Features and Survival from Hepatocellular Carcinoma after Curative Hepatectomy.

The Mechanism of APOBEC3B in Hepatitis B Virus Infection and HBV Related Hepatocellular Carcinoma Progression, Therapeutic and Prognostic Potential

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma

Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody

Overexpression of Apobec3f in Tumor Tissues is Potentially Predictive for Poor Recurrence-Free Survival from Hbv-Related Hepatocellular Carcinoma

Multi-Omic Analyses Of The M(5)C Regulator Alyref Reveal Its Essential Roles In Hepatocellular Carcinoma

IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p

APOBEC3B: Future direction of liver cancer research

IL‐6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma

Table S5 from Genetic Polymorphisms Predisposing the Interleukin 6–induced APOBEC3B-UNG Imbalance Increase HCC Risk Via Promoting the Generation of APOBEC-Signature HBV Mutations

Association of Human APOBEC3 Cytidine Deaminases with the Generation of Hepatitis Virus B X Antigen Mutants and Hepatocellular Carcinoma

Interleukin-6 Induced Proliferation Is Attenuated by Transforming Growth Factor-β-Induced Signaling in Human Hepatocellular Carcinoma Cells

ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression

Table S12 from Genetic Polymorphisms Predisposing the Interleukin 6–induced APOBEC3B-UNG Imbalance Increase HCC Risk Via Promoting the Generation of APOBEC-Signature HBV Mutations

Diagnostic and prognostic significance of mRNA expressions of apolipoprotein A and C family genes in hepatitis B virus-related hepatocellular carcinoma